New Protocols (0*)

* The protocols may appear repeatedly under different diseases

Updated Protocols (5*)

* The protocols may appear repeatedly under different diseases

Lung Carcinoma, Small Cell

Serplulimab 4.5 / Carboplatin 5 / Etoposide 100, Small Cell Lung Cancer PID 2922 V1.1 (2026-04-29)
V1.1: Title correction. Olanzapine added for antiemesis. V1.0: Dosing according to primary literature, run times according to the summary of product characteristics.
Serplulimab 4.5, Small Cell Lung Cancer, Maintenance PID 2923 V1.1 (2026-04-29)
V1.1: Title correction. V1.0: Dosing according to primary literature, running times according to the summary of product characteristics.

Multiple Myeloma

CEPHEUS - Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Cycle 1-2 PID 2979 V1.1 (2026-05-04)
V1.1: Protocol title changed, infection prophylaxis added V1.0: Application according to primary literature
CEPHEUS - Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Cycle 3-8 PID 2980 V1.1 (2026-05-04)
V1.1: Protocol title changed, infection prophylaxis added V1.0: Application according to primary literature
CEPHEUS - Daratumumab 1800 / Lenalidomide 25 / Dexamethasone 40, Multiple Myeloma, Cycle 9+ PID 2981 V1.1 (2026-05-04)
V1.1: Protocol title changed, infection prophylaxis added V1.0: Application according to primary literature

Protocols in Revision

Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

AMPLIFY - Acalabrutinib 100 / Obinutuzumab (100/900/1000), Chronic Lymphocytic Leukemia, Cycle 2 PID 2847 V1.1
AMPLIFY - Acalabrutinib 100 / Obinutuzumab 1000 / Venetoclax (20/50/100/200), Chronic Lymphocytic Leukemia, Cycle 3 PID 2845 V1.1
AMPLIFY - Acalabrutinib 100 / Obinutuzumab 1000 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 4-7 PID 2846 V1.1
AMPLIFY - Acalabrutinib 100 / Venetoclax (20/50/100/200), Chronic Lymphocytic Leukemia, Cycle 3 PID 2842 V1.1
AMPLIFY - Acalabrutinib 100 / Venetoclax 400, Chronic Lymphocytic Leukemia, Cycle 4-14 PID 2843 V1.1
AMPLIFY - Acalabrutinib 100, Chronic Lymphocytic Leukemia, Cycle 1 PID 2844 V1.1
AMPLIFY - Acalabrutinib 100, Chronic Lymphocytic Leukemia, Cycle 1-2 PID 2841 V1.1
ELEVATE TN - Acalabrutinib 100 / Obinutuzumab (100/900/1000), Chronic Lymphocytic Leukemia, Cycle 2 PID 1655 V1.3
ELEVATE TN - Acalabrutinib 100 / Obinutuzumab 1000, Chronic Lymphocytic Leukemia, Cycle 3-7 PID 1656 V1.2
ELEVATE TN - Acalabrutinib 100, Chronic Lymphocytic Leukemia PID 1653 V1.2
ELEVATE TN - Acalabrutinib 100, Chronic Lymphocytic Leukemia, Cycle 1 PID 1654 V1.2

Hodgkin Lymphoma

mini-BEAM - Carmustine 60 / Etoposide 75 / Cytarabine 100 / Melphalan 30, Hodgkin Lymphoma PID 2381 V1.1

Multiple Myeloma

AURIGA - Daratumumab 1800 / Lenalidomide 10, multiple myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 1-2 PID 2796 V1.1
AURIGA - Daratumumab 1800 / Lenalidomide 10, Multiple Myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 3-6 PID 2797 V1.1
AURIGA - Daratumumab 1800 / Lenalidomide 10, Multiple Myeloma, maintenance after Stem Cell Transplantation, Autologous, Cycle 7+ PID 2798 V1.1
ELOQUENT-2 - Elotuzumab 10 / Lenalidomide 25 / Dexamethasone (28/40), Multiple Myeloma Cycle 3+ PID 702 V1.4
ELOQUENT-2 - Elotuzumab 10 / Lenalidomide 25 / Dexamethasone 28, Multiple Myeloma Cycle 1-2 PID 701 V1.4
ELOQUENT-3 - Elotuzumab 10 / Pomalidomide 4 / Dexamethasone 28, Multiple Myeloma Cycle 1-2 PID 1227 V1.4
ELOQUENT-3 - Elotuzumab 20 / Pomalidomide 4 / Dexamethasone 28, Multiple Myeloma Cycle 3+ PID 1229 V1.4
GRIFFIN - Bortezomib 1.3 / Daratumumab (8/8/16) / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Induction, Cycle 1 PID 1718 V1.2
GRIFFIN - Bortezomib 1.3 / Daratumumab 16 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 2-4 PID 1719 V1.2
GRIFFIN - Bortezomib 1.3 / Daratumumab 16 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, consolidation, cycle 5-6 PID 1720 V1.2
GRIFFIN - Bortezomib 1.3 / Daratumumab 1800 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 1-4 PID 1723 V1.2
GRIFFIN - Bortezomib 1.3 / Daratumumab 1800 / Lenalidomide 25 / Dexamethasone 20, multiple Myeloma, consolidation cycle 5-6 PID 1724 V1.2
GRIFFIN - Daratumumab 16 / Lenalidomide 10, Multiple Myeloma, maintenance PID 1721 V1.3
GRIFFIN - Daratumumab 1800 / Lenalidomide 10, Multiple Myeloma, maintenance PID 1725 V1.3
HD 7 - Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, Induction, Cycle 1-3 PID 40 V1.1
HD 7 - Lenalidomide 10 / Dexamethasone 20, Multiple Myeloma, maintenance, cycle 1 PID 43 V1.1
HD 7 - Lenalidomide 10, multiple myeloma, maintenance, cycle 2-3 PID 44 V1.1
HD 7 - Lenalidomide 15, multiple myeloma, maintenance, cycle 4+ PID 37 V1.1
IMROZ - Bortezomib 1.3 / Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle PID 2660 V1.1
IMROZ - Bortezomib 1.3 / Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, multiple myeloma, induction, cycle 2-4 PID 2661 V1.1
IMROZ - Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, maintenance, cycle 18+ PID 2663 V1.1
IMROZ - Isatuximab 10 / Lenalidomide 25 / Dexamethasone 20, Multiple Myeloma, maintenance, cycle 5-17 PID 2662 V1.1
PERSEUS - Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 40 - Daratumumab 1800 / Lenalidomide 10, multiple Myeloma, maintenance PID 2519 V1.1
PERSEUS - Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 40, multiple myeloma, induction, cycle 1-2 PID 2516 V1.1
PERSEUS - Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 40, multiple myeloma, induction, cycle 3-4 PID 2517 V1.1
PERSEUS - Daratumumab 1800 / Bortezomib 1.3 / Lenalidomide 25 / Dexamethasone 40, multiple myeloma, consolidation, cycle 5-6 PID 2518 V1.1

NHL, T-cell type

CHP - Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma PID 1204 V1.1

NHL, T-Cell Type, Adult T-Cell Leukemia or Lymphoma

CHP - Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma PID 1204 V1.1

NHL, T-Cell Type, Anaplastic Large Cell

CHP - Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma PID 1204 V1.1

NHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK negative

CHP - Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma PID 1204 V1.1

NHL, T-Cell Type, Anaplastic Large Cell Lymphoma, ALK-positive

CHP - Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma PID 1204 V1.1

NHL, T-Cell Type, Angioimmunoblastic

CHP - Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma PID 1204 V1.1

NHL, T-Cell Type, Enteropathy Type

CHP - Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma PID 1204 V1.1

NHL, T-Cell Type, Hepatosplenic

CHP - Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma PID 1204 V1.1

NHL, T-Cell Type, Peripheral, Unspecified

CHP - Cyclophosphamide 750 / Doxorubicin 50 / Prednisolone 100 / Brentuximab Vedotin 1.8, T-cell Lymphoma PID 1204 V1.1